Avantor (AVTR) AI Stock Analysis

• Market Cap: $7.53B
• Dividend Yield: N/A
• Average Volume (3M): 11.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: -3.59%
• EPS Growth: -126.16%
• Country: US
• Employees: 13,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.22
• Shares Outstanding: 681,738,650
• 10 Day Avg. Volume: 15,009,926
• 30 Day Avg. Volume: 11,461,089
• PEG Ratio: 0.17
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 2.11
• P/FCF Ratio: 20.71
• Enterprise Value/Market Cap: 1.61
• Enterprise Value/Revenue: 1.82
• Enterprise Value/Gross Profit: 5.47
• Enterprise Value/Ebitda: 8.59
• 1Y Price Target: $13.85
• Price Target Upside: 25.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 15

• Rating: 53 Neutral
• Price Target: $11.00 ▼(-0.45% Downside)

Avantor's overall stock score is primarily impacted by its mixed financial performance and bearish technical indicators. The negative valuation metrics and challenges highlighted in the earnings call further weigh on the score. While strategic initiatives are in place, near-term performance remains under pressure.

Positive Factors

Share Repurchase Program

The share repurchase program indicates management's confidence in the company's long-term prospects and can enhance shareholder value by reducing the number of shares outstanding.

Cost Control and Cash Flow

Strong cost control and cash flow conversion highlight operational efficiency, which supports financial stability and provides resources for strategic investments.

Debt Refinancing

Successful debt refinancing and extending maturity to 2030 improve financial flexibility and reduce refinancing risk, supporting long-term financial health.

Negative Factors

Revenue Decline

A decline in revenue indicates challenges in maintaining market position and growth, potentially impacting profitability and competitive standing over time.

Goodwill Impairment

Significant goodwill impairment reflects underlying business challenges and may indicate overvaluation of past acquisitions, affecting future earnings potential.

Operational Challenges

Persistent operational challenges can hinder production efficiency and market responsiveness, impacting long-term growth and competitive advantage.

Avantor Business Overview & Revenue Model

Company Description

Avantor, Inc. (AVTR) is a global provider of mission-critical products and services to customers in the life sciences and advanced technology sectors. The company operates in two main segments: Life Sciences and Advanced Technologies. Avantor offers a comprehensive portfolio of high-quality laboratory supplies, chemicals, and consumables, as well as specialized services and solutions that support research, development, and production processes across various industries, including pharmaceuticals, biotechnology, and materials science.

How the Company Makes Money

Avantor generates revenue through multiple key streams, primarily by selling a wide range of laboratory products and supplies, including reagents, consumables, and equipment to customers in the life sciences and advanced technologies sectors. The company also provides specialized services, such as custom manufacturing, supply chain management, and laboratory services, which contribute to its revenue. Avantor has established significant partnerships with leading pharmaceutical and biotechnology companies, enabling it to secure long-term contracts and enhance customer loyalty. Additionally, the company's focus on innovation and expansion into emerging markets further drives its growth and revenue generation.

Avantor Financial Statement Overview

Summary

Avantor's financial performance is mixed. While the company maintains healthy margins and improved leverage, challenges in revenue growth and cash flow generation are concerning. The decline in revenue and free cash flow growth could pose risks if not addressed.

Income Statement

Avantor's income statement shows a mixed performance. The gross profit margin is stable at around 33%, indicating consistent cost management. However, the net profit margin has slightly decreased to 10.3% in the TTM, reflecting some pressure on profitability. Revenue has declined by 2.9% in the TTM, suggesting challenges in maintaining growth. The EBIT and EBITDA margins are healthy, but the decline in revenue growth is a concern.

Balance Sheet

The balance sheet reflects a moderate financial position. The debt-to-equity ratio has improved to 0.67 in the TTM, indicating better leverage management. Return on equity is reasonable at 11.5%, showing effective use of equity. The equity ratio is stable, suggesting a balanced asset structure. Overall, the balance sheet shows improvement in leverage, but there is room for enhancing equity returns.

Cash Flow

Cash flow analysis reveals some concerns. Free cash flow has decreased by 16.6% in the TTM, indicating potential cash generation issues. The operating cash flow to net income ratio is low at 0.26, suggesting limited cash conversion efficiency. However, the free cash flow to net income ratio remains strong at 81.5%, highlighting decent cash profitability despite growth challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.67B	6.78B	6.97B	7.51B	7.39B	6.39B
Gross Profit	2.22B	2.28B	2.36B	2.60B	2.50B	2.08B
EBITDA	1.41B	1.48B	1.10B	1.52B	1.35B	765.30M
Net Income	687.40M	711.50M	321.10M	686.50M	572.60M	116.60M
Balance Sheet
Total Assets	12.78B	12.11B	12.97B	13.46B	13.90B	9.91B
Cash, Cash Equivalents and Short-Term Investments	449.40M	261.90M	262.90M	372.90M	301.70M	286.60M
Total Debt	4.24B	4.23B	5.54B	6.29B	7.02B	4.89B
Total Liabilities	6.49B	6.16B	7.72B	8.61B	9.70B	7.23B
Stockholders Equity	6.29B	5.96B	5.25B	4.86B	4.20B	2.67B
Cash Flow
Free Cash Flow	555.90M	692.00M	723.60M	710.20M	842.50M	868.20M
Operating Cash Flow	681.80M	840.80M	870.00M	843.60M	953.60M	929.80M
Investing Cash Flow	460.50M	438.90M	-143.70M	-109.60M	-4.12B	-59.10M
Financing Cash Flow	-994.40M	-1.28B	-843.70M	-648.70M	3.22B	-782.90M

Avantor Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTR, the sentiment is Negative. The current price of 11.05 is below the 20-day moving average (MA) of 14.03, below the 50-day MA of 13.32, and below the 200-day MA of 14.68, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 37.02 is Neutral, neither overbought nor oversold. The STOCH value of 7.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVTR.

Avantor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EMN	―	$6.83B	8.36	14.52%	5.56%	1.60%	-3.97%
KWR	―	$2.27B	―	-0.52%	1.56%	-3.09%	-106.46%
SQM	―	$13.32B	29.28	9.29%	―	-23.20%	1226.72%
ALB	―	$11.56B	-10.53	-8.66%	1.68%	-33.05%	-97.63%
AVTR	―	$7.53B	―	-1.48%	―	-3.59%	-126.16%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WLK	―	$8.76B	―	-0.64%	3.08%	-3.00%	-124.79%

Avantor Corporate Events

Avantor’s Earnings Call: Strategic Moves Amid Challenges

Avantor’s recent earnings call painted a picture of strategic ambition tempered by significant operational hurdles. The company is clearly focused on long-term stability and improvement, yet it faces persistent challenges such as revenue declines and goodwill impairments that need addressing.

Avantor Reports Q3 2025 Results Amid Strategic Changes

Avantor, Inc. is a global leader in providing essential products and services to the life sciences and advanced technology industries, facilitating breakthroughs in medicine, healthcare, and technology across more than 300,000 customer locations worldwide.

Avantor Announces Major Credit Agreement Amendment

Avantor Funding, Inc., a subsidiary of Avantor, Inc., announced an amendment to its credit agreement on October 9, 2025, which includes new revolving credit commitments totaling $1.4 billion and additional Euro term loans. The amendment extends maturity dates and aims to refinance existing debt, enhance liquidity, and support ongoing business operations. The agreement includes customary covenants and guarantees by subsidiaries, with security interests in assets.

The most recent analyst rating on (AVTR) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Avantor stock, see the AVTR Stock Forecast page.

Avantor Announces Upcoming Leadership Change

Avantor, Inc. announced that Jonathan Peacock will step down as chairman, member of the Board of Directors, and member of the Nominating and Governance Committee on December 31, 2025. This decision was not due to any disagreements with the company. Gregory L. Summe, a current board member, will assume the role of chairman starting January 1, 2026.

The most recent analyst rating on (AVTR) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Avantor stock, see the AVTR Stock Forecast page.

Avantor Appoints Gregory Lucier to Board of Directors

Avantor, Inc. announced the election of Gregory Lucier to its Board of Directors, effective October 3, 2025. Lucier, with extensive leadership experience in the medical and life sciences sectors, is expected to bring valuable insights to Avantor. His appointment aligns with Avantor’s strategic focus on enhancing its governance and leadership capabilities. The company confirmed that Lucier meets all necessary independence standards, and he will receive standard compensation for non-employee directors.

The most recent analyst rating on (AVTR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Avantor stock, see the AVTR Stock Forecast page.

Avantor Appoints Emmanuel Ligner as CEO and Director

On August 7, 2025, Avantor, Inc. announced the election of Emmanuel Ligner to its Board of Directors, with his term starting on August 18, 2025, and lasting until the 2026 Annual Meeting of Stockholders. Mr. Ligner will also serve as the company’s President and CEO, filling a vacant board seat without additional compensation. His appointment follows a previous report and does not involve any arrangements or material interests requiring disclosure.

The most recent analyst rating on (AVTR) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Avantor stock, see the AVTR Stock Forecast page.

Avantor Reports Q2 2025 Financial Results

Avantor, Inc. is a prominent global provider of essential products and services for the life sciences and advanced technology sectors, facilitating breakthroughs in medicine, healthcare, and technology across 180 countries.

Avantor’s Earnings Call: Mixed Sentiments and Strategic Moves

Avantor’s earnings call presented a mixed sentiment, highlighting both achievements and challenges. The company reported sequential improvements in organic revenue growth and secured significant contract extensions, yet faced difficulties in its bioprocessing segment and revised its guidance downwards. The strategic focus on maintaining market share impacted margins, reflecting a challenging operating environment.